RxDoctor Payments Data

Mary Varghese, NP

Nurse Practitioner · Travelers Rest, SCNPI 1548600547

Payments from drug & device makers

$1,715in general payments, 2019–2025

Across 108 payments — averaging $15.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$303
  • Bayer$222
  • AbbVie$202
  • Lilly USA, LLC$197
  • AstraZeneca$169
  • Boehringer Ingelheim$101
  • plus $520 from 13 others

What the payments were for

  • Food & beverage$1,715100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,715 in reported general payments places this provider in the 80th percentile of 1,346 nurse practitioner providers in South Carolina.

See all nurse practitioner providers in South Carolina

Medicare billing

Part B allowed, 2024
$70,720
Medicare patients
300
Services billed
1,123

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin145$128,910
EliquisApixaban71$53,295
MounjaroTirzepatide44$51,071
OzempicSemaglutide44$41,215
FarxigaDapagliflozin Propanediol45$35,131
TrulicityDulaglutide28$30,187
XareltoRivaroxaban38$26,988
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$24,109
Repatha SyringeEvolocumab40$23,555
MyrbetriqMirabegron27$12,819
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog18$12,359
Tresiba Flextouch U-100Insulin Degludec15$10,152
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$9,904
Lantus SolostarInsulin Glargine,hum.Rec.Anlog46$6,167
Varenicline Tartrate19$5,028

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$101$128,910145 claims
Lilly USA, LLCMounjaro, Trulicity$197$81,25772 claims
PfizerEliquis$34$53,29571 claims
Novo NordiskOzempic$303$41,21544 claims
AstraZenecaFarxiga$169$35,13145 claims
GSKTrelegy Ellipta$32$24,10929 claims
AbbVieSynthroid$202$2,41930 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,346 nurse practitioner providers in South Carolina.

Other nurse practitioner in Travelers Rest

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →